Palliative Care
Study register · detail Kohortenstudie · Palliative Care · 2022

Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.

Mixed GRADE Low 1 citations
Samplen = 491 Pat.
DurationFollow-up September 2019 to…
ControlStandard palliative pain therapy without…
EndpointOverall survival
Blindingn.a.
DesignKohortenstudie
Key finding

Cannabis group showed longer median survival time (5,66 vs. 0,83 months) and lower mortality rate, but authors warn of unmeasured confounding and call for prospective studies to confirm.

Summary

Retrospective cohort on medical cannabis in advanced cholangiocellular carcinoma (CCA), n=491 (87 cannabis therapy CT, 404 standard palliative care ST). Median survival CT=5.66 months (95% CI: 1.94–9.38) vs. ST=0.83 months (95% CI: 0.71–0.95). Multivariate analysis: CT associated with prolonged survival (HRadj=0.28; 95% CI: 0.20–0.37; p<0.001). Mortality rate CT=10.9/100 person-months vs. ST=48.35/100 person-months. Authors emphasize possible residual confounding.

P
PopulationAdults with advanced cholangiocarcinoma (CCA), newly diagnosed, n=491 (ST: n=404, CT: n=87), Northeast Thailand
I
InterventionMedical cannabis (palliative treatment, CT group, n=87)
C
ControlStandard palliative pain therapy without cannabis (ST group, n=404)
O
OutcomeMedian survival: 5,66 months (CT) vs. 0,83 months (ST); adjusted HR=0,28 (95% CI: 0,20–0,37; p<0,001)
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size
Blinding
Effect size Mixed
Citations / year
Authors
Phansila N, Pansila P, Wongkongdech A, Turnbull N, Azam M, Wongkongdech R
DOI 10.12688/f1000research.123250.3
Design: Kohortenstudie
Share
Abstract
Background: Cholangiocarcinoma (CCA) incidence in Northeastern Thailand is very high and a major cause of mortality. CCA patients typically have a poor prognosis and short-term survival rate due to late-stage diagnosis. Thailand is the first Southeast Asian country to approve medicinal cannabis treatment, especially for palliative care with advanced cancer patients. Methods: A retrospective cohort study compared survival among 491 newly diagnosed advanced CCA patients between September 2019 and June 2021. Of these, 404 received standard palliative pain management (ST), and 87 received medicinal cannabis treatment (CT). Patients were enrolled from four tertiary hospitals and two secondary hospitals in five provinces of Northeast Thailand. Cumulative survival was calculated by the Kaplan-Meier method, and independent prognostic factors were analyzed using Cox regression. Results: For ST patients, follow-up time was 790 person-months, with a mortality rate of 48.35/100 person-months. For CT patients, follow-up time was 476 person-months, with a mortality rate of 10.9/100 person-months. The median survival time after registration at a palliative clinic was 0.83 months (95% CI: 0.71-0.95) for ST and 5.66 months (95% CI: 1.94-9.38) for CT. Multivariate analysis showed CT was significantly associated with prolonged survival (HRadj = 0.28; 95% CI: 0.20-0.37; p < 0.001). Conclusions: The medical cannabis increased overall survival rates among CCA patients. In this retrospective cohort, Medicinal cannabis treatment was associated with more prolonged survival among advanced CCA patients in Northeastern Thailand. While this association remained significant after multivariable adjustment, unmeasured or residual confounding factors may have influenced the observed outcomes. Although the association remained significant after adjustment, unmeasured or residual confounders may have influenced outcomes. Further prospective studies are warranted to confirm these findings and explore potential mechanisms.

The impediment to action advances action. — Marcus Aurelius